Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
about
Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitorPanobinostat for the treatment of multiple myeloma: the evidence to dateIntegrating Domain Specific Knowledge and Network Analysis to Predict Drug Sensitivity of Cancer Cell LinesDual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndromePhase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer.A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myelomaPhase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat.Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function.Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1.Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors.Antagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cellsHighly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and PanobinostatProfile of panobinostat and its potential for treatment in solid tumors: an update.Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment.Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.Deacetylase inhibitors for the treatment of myelodysplastic syndromes.Panobinostat: a review of trial results and future prospects in multiple myeloma.Panobinostat: first global approval.Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.Panobinostat for the management of multiple myeloma.Emerging biological therapies for the treatment of myelodysplastic syndromes.Panobinostat for the treatment of acute myelogenous leukemia.Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives.Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.Novel agents in classical Hodgkin lymphoma.
P2860
Q26747768-3151CAF2-83B5-470F-A226-5CFCA41C26D9Q26778674-988D01CE-BDA2-4F6B-B1B2-C261C38D9CC1Q28553930-E8233222-45C2-4708-9BE8-B77E86F2A4BCQ33163717-FBB31A58-8DA4-4C2F-9944-3E0A3FB942E9Q33407924-2EF2D5E3-E8F4-4DE3-940D-30113E39F237Q33410761-1423AFCD-D66F-4AB1-B266-3DBD878D909EQ33410898-E196DA6C-B3CF-4D7E-BD09-C1C8F0033B9EQ33410997-09CB0AD1-8434-4848-A8D9-6D748AFD0EDDQ33426983-C6A8BDD8-8253-447B-BCB2-034C339E3593Q33437309-65880EA1-9195-498D-9AAB-3C1C17B96C29Q33443179-79ED9040-D6B2-496D-A117-CA571F1476A9Q33570005-87483671-1E11-41F9-AE70-684D79C2CA81Q34194704-B813BA1A-9DCD-4614-9C88-D469313ECF8AQ34199935-B65DDF80-D3DF-4DB6-BC9E-3AC72DCCAB24Q34602263-4C96E5D5-D335-4E23-B43A-D9523C6D83CBQ35103991-851FA6A3-EE41-42AB-95FF-9AB290149E6CQ35603293-BCDD9884-ABB8-4A88-B593-1F41F2FB2459Q35677279-C0201965-2BAB-4C5C-A9EA-0570B1A04076Q36539785-DAEF7EA8-9B07-4674-8A73-83F54E401B66Q37199772-5BF5EAEA-40C2-4A6D-B9D5-C2A0B5F6964AQ37324186-1BD0CEE3-670A-45D7-A281-F9E33ACD23D9Q37615574-48604FB1-6E3F-486F-8E57-B6B5E551A1FBQ38161731-F1F6E1CF-B3E8-4AEC-96C2-110949168774Q38233492-3CFFDB82-A892-4E06-982E-5EDC4659B339Q38269612-3B77F5D6-A3C9-47A3-A369-FC60CB87B777Q38403118-F2AD17B3-0E5F-46F3-95D6-F694E3EA033BQ38519497-B5FBF228-F8BF-4D56-B890-24C0EC724C47Q38572855-317F5BC0-12EF-4591-9FC7-628BD2BE62EDQ38595978-1CF84395-734E-451B-B25B-12C2AB3870C6Q38616807-7613D3D7-B8CC-4977-A509-4ED4CDA4EA9FQ38710509-821B2993-A603-4B6C-B043-35DBF998CCA8Q38765451-841D6953-5190-442F-9BAF-9E452772792AQ38806260-E54C6106-FC0E-454D-B39B-BB8C7B127DEBQ38834981-26B78456-2E37-4A61-8B42-F0755C31D6EEQ38835113-BACDD15C-7ABC-414A-B359-D804974978DAQ38844615-B3005637-D2C7-49F2-B149-E9D44FC54E22Q38856941-A303F8F2-AD62-4B91-8836-42576E947563Q38906418-1FA19B96-2A5F-40C0-AA71-A20A269CD342Q39062353-2C3EE3A5-CCB2-4F12-A8F5-62CC9CFCF746Q39187452-7CC5C985-0246-4EDC-8592-FF21D584BD0B
P2860
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Phase Ia/II, two-arm, open-lab ...... nced hematologic malignancies.
@ast
Phase Ia/II, two-arm, open-lab ...... nced hematologic malignancies.
@en
type
label
Phase Ia/II, two-arm, open-lab ...... nced hematologic malignancies.
@ast
Phase Ia/II, two-arm, open-lab ...... nced hematologic malignancies.
@en
prefLabel
Phase Ia/II, two-arm, open-lab ...... nced hematologic malignancies.
@ast
Phase Ia/II, two-arm, open-lab ...... nced hematologic malignancies.
@en
P2093
P2860
P356
P1433
P1476
Phase Ia/II, two-arm, open-lab ...... anced hematologic malignancies
@en
P2093
D J DeAngelo
H M Prince
K K Mishra
K N Bhalla
P2860
P2888
P304
P356
10.1038/LEU.2013.38
P577
2013-02-06T00:00:00Z
P6179
1016702347